ARA-290
Cibinetide · Non-hematopoietic EPO peptide
Engineered EPO-derived peptide that provides tissue protection and neuropathy relief without red blood cell stimulation.
Half-Life
~3–4 hours
MW
N/A
Amino Acids
N/A
Evidence
Clinical
Regulatory Status
Phase 2/3 clinical trials (EU, sarcoidosis neuropathy)
In Plain English
A piece of the EPO hormone re-engineered to give all its tissue-protection benefits without stimulating red blood cell production. Has shown genuine promise for nerve pain in Phase 2/3 clinical trials for sarcoidosis-related neuropathy.
Overview
ARA-290 (Cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) — a tissue-protective receptor distinct from the classical EPO receptor. It provides anti-inflammatory and tissue-regenerative effects without stimulating erythropoiesis (red blood cell production). Clinical trials have shown promising results for small fiber neuropathy and sarcoidosis-associated neuropathy.
Common Formats
- Injectable (subcutaneous)
Storage Notes
Refrigerate. Use within 30 days of reconstitution.
Looking for multi-compound protocols?
Browse educational protocol discussions that include ARA-290.
Research Sources
(3 vendors)For research use only. No affiliation or endorsement implied.
Related Compounds
BPC-157
A 15 amino acid peptide derived from human gastric juice, widely researched for its tissue-healing and cytoprotective properties.
TB-500
A synthetic version of the naturally occurring peptide Thymosin Beta-4, studied for tissue repair, inflammation reduction, and vascular remodeling.
LL-37
The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity, immunomodulation, and wound-healing properties.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.